Earth Science Tech (OTC: ETST) recently reported Q1 2027 results that management says demonstrate continued progress from its strategy of acquiring and scaling profitable healthcare, pharmaceutical, and telemedicine businesses. For the quarter ended June 30, 2026, revenue rose 3% to $9.0 million, gross profit increased 3.1% to $6.3 million, net income climbed 57% to $715,697, operating cash flow more than doubled to $707,131, and total assets grew 33.3% to $10.4 million compared with Q1 2026. Looking ahead, ETST plans to expand geographically, develop its telehealth and pharmacy fulfillment platforms, improve operating efficiency, and pursue greater institutional investor participation.
To view the full article, visit https://ibn.fm/LBl8r
About Earth Science Tech Inc.
Earth Science Tech operates as a diversified holding company focused on the health and wellness sector. The company’s principal operating strategy is to build a vertically integrated healthcare platform that combines compounding pharmacy operations, telemedicine platforms, clinical support, and direct-to-patient fulfillment. The company’s healthcare operations are supported by investments in real estate and asset management activities and a consumer products business.
The core of the company’s value proposition is the seamless integration of patient care, from consultation to fulfillment. This is achieved through the synergy of specialized subsidiaries.
To learn more, please visit www.EarthScienceTech.com.
NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on tissue repair solutions, announced…
Quantum BioPharma (NASDAQ: QNTM) announced that it has filed a supplement to its Sept. 28,…
Earth Science Tech (OTCQB: ETST), a diversified holding company operating across healthcare, pharmacy, technology, telemedicine,…
Disseminated on behalf of Adaptogenics Health Corp. and may include paid advertising. Adaptogenics (CSE: ADPT)…
VERAXA Biotech (NASDAQ: VRXA) is expanding its use of human-relevant preclinical testing methods across its…
Quantum BioPharma (NASDAQ: QNTM) has signed a Study Start-Up Agreement with Thermo Fisher Scientific’s clinical…